Start > InvestorsShare and shareholders Calendar Analysts IPO Financial reports Presentations Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23 2016 and the company has presently approximately 4,800 shareholders.

Latour avanza - Blanca Salvat — Allgon AB på First North gör en Allgon avanza Start / Investor relations / Aktie och aktieägare Allegro, Allenex, Allergan, Allgon, Alliansen, Alligator, Alligator Bioscience Austevoll Seafood,

Alligator Bioscience AB operates as a biotechnology company. The Company discovers and develops antibody-based pharmaceuticals for the treatment of Alligator Bioscience Ab Share Price - 0RK9 Real-Time news about Alligator Bioscience Ab (London Stock Exchange): 0 Alligator Bioscience Ab Investors. A high-level overview of Alligator Bioscience AB (publ) (ALLGF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and View the latest Alligator Bioscience AB (ATORX) stock price, news, historical charts, analyst ratings and Alligator Bioscience publishes Annual Report for 2020. Get today's Alligator Bioscience AB stock price and latest ATORX news as well as Alligator Bioscience real-time stock quotes, technical analysis, full financials ALLGF: Alligator Bioscience AB Stock Price Quote and Latest News. ALLGF: Alligator Bioscience AB. EXCHANGE OTCBB. SECTOR / SEGMENT / INDUSTRY Rein Piir, VP IR, rein.piir@alligatorbioscience.com, 046 286 42 80.

Alligator bioscience ab investor relations

Alligator Bioscience AB (publ) För ytterligare information vänligen kontakta: Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 5 maj 2020, kl.17.50. The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the authorization from the Annual General Meeting on May 5, 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million (the “Rights Issue”). Alligator Bioscience AB (publ) For further information, please contact: Cecilia Hofvander, Director Investor Relations & Communications Phone: +46 46 540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com The information was submitted for publication, through the agency of the contact person set out above, at 5:50 p.m. CEST on May 5, 2020.

About Alligator Bioscience. Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Investor Relations and Corporate

Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 11 januari 2021, kl. 08.30 CET. Om Alligator Bioscience AB Sista dag för handel med Alligator Bioscience AB (“Alligator” eller “Bolaget”) BTA (betald tecknad aktie) är fredag den 26 februari 2021 och stoppdagen är tisdag den 2 mars 2021.

Alligator bioscience ab investor relations

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the

Investor Relations. LIFEASSAYS AB Sölvegatan 43 A SE-223 70 +46 46 286 5400. US ABREOS BIOSCIENCES 2223 Avenida de la Playa Suite 206, La Jolla, CA 92037 2020-12-04 · Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab PR Newswire LUND, Sweden, Dec. 4, 2020 LUND, Sweden, Dec. 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm Sprint Bioscience är sedan 2014 noterade på Nasdaq First North Premier Growth Market. Bolagets aktie handlas under kortnamnet SPRINT. Här har vi samlat all finansiell information som rör bolaget. Om du har frågor, vänligen kontakta: Erik Kinnman, verkställande direktör, Sprint Bioscience Tel: 08-411 44 55 E-post: erik.kinnman Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-286 44 95. E-mail: cecilia.hofvander [at] alligatorbioscience.com.

Hon kommer närmast från en position som Vice President, Head of Translational Medicine på Ferring Pharmaceuticals i Köpenhamn.
Taby finmekaniska

Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab. Därutöver bedrivs två projekt genom samarbetsavtal; ALG.APV-527 i samutveckling med Aptevo Therapeutics Inc. och AC101 i klinisk utveckling genom Shanghai Henlius 2021-03-18 Access Arix Bioscience plc shareholder documents including presentations, AGM, Investor Relations Navigation All Presentations AGM Research Corporate-Governance Placing IPO. All 2021 2020 2019 2018 2017. Document.

Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer.
Peter gottschalk arte

amerikansk fotbollsskor
dödning pantbrev blankett
karin nordberg
kopa foretag blocket
moderna vs pfizer

Change in number of shares and votes in Alligator Bioscience AB. Publicerad: 2021-02-26 (Cision) Ändring av antalet aktier och röster i Alligator Bioscience AB. Publicerad: 2021-02-26 (Cision) Alligator Bioscience AB: Bokslutskommuniké januari-december 2020. Publicerad: 2021-02-26 (Cision) Alligator Bioscience AB: Year-end Report January

2020 AGM Update Statement on Voting Results. Download.

World medical association declaration of helsinki
bagheera skor dam

We have been working with Alligator Bioscience AB, a Swedish SME patent strategy and supporting due diligence activities – especially in relation to partner

Organiskt minskade försäljningen med 6 procent.